Fields Buys NVDA While McClain Targets IBRX Before Reports

Congressional portfolios are showing fresh conviction in both artificial intelligence infrastructure and next-generation biotech ahead of imminent earnings reports. Rep. Cleo Fields has recorded three separate purchases of NVDA, while Rep. Lisa McClain executed two buys of IBRX. These transactions stand out within a wider set of 28 filings across technology and healthcare names that coincide with approaching quarterly releases. The timing of the buys overlaps with consensus forecasts that point to continued expansion at both companies. NVDA is slated to report after market close on November 18 while IBRX is expected in the first week of November. Fields' activity in NVDA arrives as Wall Street models call for roughly $2.49 in EPS and $108.8 billion in revenue for the quarter. That revenue figure would represent approximately 90 percent year-over-year growth, driven by data-center demand and the Blackwell platform ramp. The stock has a history of beating estimates, including the most recent quarter that topped forecasts by $0.13 per share on $96.22 billion in sales. Congressional purchases at current levels therefore appear calibrated for another upside surprise and sustained AI capital spending. McClain's IBRX buys reflect a parallel healthcare bet. Analysts forecast revenue between $59 million and $62 million, an 85 percent-plus increase from the prior-year period, even as the company is expected to report another quarterly loss near seven to eight cents per share. Earlier results showed ImmunityBio beating revenue estimates while management highlighted progress toward treating advanced cancers. Price targets from firms covering the name cluster around $14.25, implying material upside from recent trading levels near $8. The two purchases by McClain therefore position her for both near-term revenue momentum and longer-term clinical catalysts. The filings fit a broader earnings-watch pattern visible across the dataset. Additional buys appeared in MSFT, ORCL, and ADI, while a separate cluster of 14 trades listed under an N/A designation involved Ro Khanna, Gilbert Cisneros, James A. Himes, Kevin Hern, Suzan K. DelBene, Darrell E. Issa, and Rudy Yakym. These transactions span technology, industrials, and healthcare, suggesting lawmakers are scanning multiple sectors for post-earnings movement. Some names saw mixed buy-sell activity, such as ORCL where Khanna both bought and sold within the period. With NVDA carrying forward P/E multiples in the low teens despite triple-digit growth rates and IBRX showing analyst upgrades from Jefferies, HC Wainwright, and Piper Sandler, the congressional entries arrive at a moment of compressed valuations relative to expected growth. Public disclosures continue to surface days or weeks after execution, yet the overlap with the earnings calendar remains notable. Market participants often monitor these patterns for directional clues even though individual members cite diversified strategies or third-party managers. This is data analysis, not financial advice.